Intensity Therapeutics, Inc. (INTS)Healthcare | Biotechnology | Shelton, United States | NasdaqCM
4.25 USD
-0.02
(-0.468%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 4.25 |
Hot Take ↕ | Aug. 22, 2026, 4:58 a.m. EDT
The immediate outlook is severely clouded by a massive 95% collapse over the last two years, leaving the stock trading at a fraction of its historical value. While the balance sheet currently shows minimal debt and ample cash relative to liabilities, the business is burning significant free cash, and the recent price action reveals a fragile floor rather than a recovery trend. Analyst consensus suggests a potential rebound to the mid-teens, but this relies entirely on a successful clinical update for cancer therapy rather than established profitability. With no dividend history and a trajectory defined by consecutive annual declines, the investment case remains speculative and high-risk. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.147003 |
| MSTL | 0.246351 |
| AutoETS | 0.262306 |
| AutoARIMA | 0.262350 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 14.05 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.144 |
| Excess Kurtosis | -1.28 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.031 |
| Market Cap | 13,875,736 |
| Forward P/E | -2.13 |
| Beta | 3.03 |
| Website | https://intensitytherapeutics.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.3789091 |
| Address1 | 1 Enterprise Drive |
| Address2 | Suite 430 |
| All Time High | 286.0 |
| All Time Low | 3.51 |
| Ask | 5.5 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 51,050 |
| Average Daily Volume3 Month | 45,169 |
| Average Volume | 45,169 |
| Average Volume10Days | 51,050 |
| Beta | 3.031 |
| Bid | 3.17 |
| Bid Size | 2 |
| Book Value | 3.928 |
| City | Shelton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.25 |
| Current Ratio | 5.002 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 4.5786 |
| Day Low | 4.24 |
| Debt To Equity | 1.031 |
| Display Name | Intensity Therapeutics |
| Earnings Timestamp End | 1,754,596,800 |
| Earnings Timestamp Start | 1,754,596,800 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 4,441,736 |
| Eps Current Year | -3.36 |
| Eps Forward | -1.99333 |
| Eps Trailing Twelve Months | -2.0 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 203 557 3023 |
| Fifty Day Average | 4.3782 |
| Fifty Day Average Change | -0.12820005 |
| Fifty Day Average Change Percent | -0.029281452 |
| Fifty Two Week Change Percent | -37.89091 |
| Fifty Two Week High | 43.5 |
| Fifty Two Week High Change | -39.25 |
| Fifty Two Week High Change Percent | -0.90229887 |
| Fifty Two Week Low | 3.51 |
| Fifty Two Week Low Change | 0.74 |
| Fifty Two Week Low Change Percent | 0.21082622 |
| Fifty Two Week Range | 3.51 - 43.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,688,131,800,000 |
| Float Shares | 3,038,949 |
| Forward Eps | -1.99333 |
| Forward P E | -2.1321106 |
| Free Cashflow | -6,281,875 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 5 |
| Fullday Change | -0.02 |
| Fullday Change Percent | -0.468384 |
| Fullday Price | 4.25 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03771 |
| Held Percent Institutions | 0.36568 |
| Implied Shares Outstanding | 3,264,879 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-06-30 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,771,459,200 |
| Last Split Factor | 1:25 |
| Long Business Summary | Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut. |
| Long Name | Intensity Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 13,875,736 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_225412349 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -11,163,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 13,745,140 |
| Number Of Analyst Opinions | 6 |
| Open | 4.3 |
| Operating Cashflow | -8,954,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 203 221 7381 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 4.25 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 4.27 |
| Price Eps Current Year | -1.264881 |
| Price Hint | 4 |
| Price To Book | 1.0819756 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.245 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.02 |
| Regular Market Change Percent | -0.468384 |
| Regular Market Day High | 4.5786 |
| Regular Market Day Low | 4.24 |
| Regular Market Day Range | 4.24 - 4.5786 |
| Regular Market Open | 4.3 |
| Regular Market Previous Close | 4.27 |
| Regular Market Price | 4.25 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 22,422 |
| Return On Assets | -0.89913005 |
| Return On Equity | -1.95876 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 3,264,879 |
| Shares Percent Shares Out | 0.025 |
| Shares Short | 81,764 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 162,597 |
| Short Name | Intensity Therapeutics, Inc. |
| Short Percent Of Float | 0.025999999 |
| Short Ratio | 2.97 |
| Source Interval | 15 |
| State | CT |
| Symbol | INTS |
| Target High Price | 32.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 19.33333 |
| Target Median Price | 17.5 |
| Total Cash | 9,529,000 |
| Total Cash Per Share | 2.919 |
| Total Debt | 95,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.807305 |
| Two Hundred Day Average Change | -2.5573049 |
| Two Hundred Day Average Change Percent | -0.37567067 |
| Type Disp | Equity |
| Volume | 22,422 |
| Website | https://intensitytherapeutics.com |
| Zip | 06,484-4779 |